Impaired fasting glucose: Pro-diabetic, atheroprotective and modified by metabolic syndrome

Basit Öğe Kaydı
dc.contributor.authorOnat, Altan
dc.contributor.authorAydin, Mesut
dc.contributor.authorCan, Gunay
dc.contributor.authorCakmak, H. Altug
dc.contributor.authorKoroglu, Bayram
dc.contributor.authorKaya, Aysem
dc.contributor.authorAdemoglu, Evin
dc.date.accessioned2024-04-24T17:24:22Z
dc.date.available2024-04-24T17:24:22Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractAIM: To investigate whether impaired fasting glucose (IFG) confers cardiovascular risk. METHODS: A non-diabetic population-based sample representative of middle-aged and elderly Turks was studied at 8.5 years' follow-up for incident diabetes and coronary heart disease (CHD). Metabolic syndrome (MetS) was defined by ATP-III criteria modified for male abdominal obesity, and IFG and type 2 diabetes were identified by criteria of the American Diabetes Association. Stratification by presence of MetS was used. Outcomes were predicted providing estimates for hazard ratio (HR) obtained by use of Cox proportional hazards regression analysis in models that controlled for potential confounders. RESULTS: In 3181 adults (aged 52 +/- 11.5 years at baseline), analysis stratified by MetS, gender and IFG status distinguished normoglycemic subjects by a hypertriglyceridemic waist phenotype consisting of significantly higher waist circumference, fasting triglyceride and lower high-density lipoprotein-cholesterol, regardless of gender and MetS. Additionally, lipoprotein (Lp) (a) tended to be lower in (especially female) participants with MetS. Multivariable linear regression in a subset of the sample demonstrated decreased Lp (a) levels to be associated with increased fasting glucose and insulin concentrations, again particularly in women. In Cox regression analysis, compared with normoglycemia, baseline IFG adjusted for major confounders significantly predicted incident diabetes at a 3-fold HR in men and only women with MetS. Cox models for developing CHD in 339 individuals, adjusted for conventional risk factors, revealed that IFG status protected against CHD risk [HR = 0.37 (95% CI: 0.14-0.998)] in subjects free of MetS, a protection that attenuated partly in male and fully in female participants with MetS. CONCLUSION: IFG status in non-diabetic people without MetS displays reduced future CHD risk, yet is modulated by MetS, likely due to autoimmune activation linked to serum Lp (a). (C) 2013 Baishideng. All rights reserved.en_US
dc.description.sponsorshipTurkish Society of Cardiologyen_US
dc.description.sponsorshipSupported by The Turkish Society of Cardiologyen_US
dc.identifier.doi10.4239/wjd.v4.i5.210
dc.identifier.endpage218en_US
dc.identifier.issn1948-9358
dc.identifier.issue5en_US
dc.identifier.pmid24147205
dc.identifier.startpage210en_US
dc.identifier.urihttps://doi.org/10.4239/wjd.v4.i5.210
dc.identifier.urihttps://hdl.handle.net/11468/19638
dc.identifier.volume4en_US
dc.identifier.wosWOS:000219105900007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Diabetes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutoimmune Activationen_US
dc.subjectCoronary Disease Risken_US
dc.subjectDiabetesen_US
dc.subjectType 2en_US
dc.subjectImpaired Fasting Glucoseen_US
dc.subjectLipoprotein (A)en_US
dc.subjectMetabolic Syndromeen_US
dc.titleImpaired fasting glucose: Pro-diabetic, atheroprotective and modified by metabolic syndromeen_US
dc.titleImpaired fasting glucose: Pro-diabetic, atheroprotective and modified by metabolic syndrome
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu